Literature DB >> 17621412

Solitary extramedullary plasmacytoma in the oropharynx: advantages of intensity-modulated radiation therapy.

Milan Vosmik1, Melanie Cermanova, Karel Odrazka, Vladimir Maisnar, Milan Zouhar, Petr Kordac, Jiri Petera.   

Abstract

We report a case of a 59-year-old man with solitary extramedullary plasmacytoma in his oropharynx. Because the diagnosis is rare and there is only limited experience in the literature based on retrospective data, the optimal planning target volume and optimal dose of radiation therapy (RT) are still controversial. The frequently discussed problem is the necessity of first echelon lymph node irradiation because it is associated with a higher rate of complications such as xerostomia caused by damage to salivary glands. In order to prevent late toxicity, intensity-modulated RT with the use of simultaneous integrated boost and parotid salivary gland sparing was used in this patient's treatment. The RT was performed in 23 identical fractions, the primary tumor region was irradiated with a dose of 46 Gy and the first echelon lymph node region with the risk of subclinical disease with a dose of 41.4 Gy; the dose per fraction was 2 Gy and 1.8 Gy, respectively. The patient is alive and well > 20 months after the irradiation, without any evidence of disease. Parotid gland function remained intact, and no xerostomia occurred. This is the first report of the use of intensity-modulated RT with parotid gland sparing in the treatment of solitary extramedullary plasmacytoma in the head and neck region.

Entities:  

Mesh:

Year:  2007        PMID: 17621412     DOI: 10.3816/CLM.2007.n.025

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  1 in total

1.  Solitary extramedullary plasmacytoma of the parotid gland in a patient with mixed connective tissue disease.

Authors:  Dimitris Tatsis; Damianos Sotiropoulos; Aggeliki Baliaka; Ioanna Kalaitsidou
Journal:  J Oral Maxillofac Pathol       Date:  2021-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.